We concluded that the addition of roflumilast to the first-line treatment of non-GCB DLBCL patients decreases VEGF-A in the urine, a surrogate for the inhibition of angiogenesis. The gene discussed is VEGFA; the disease is diffuse large B-cell lymphoma.